Section Arrow
ANL.NASDAQ
- Adlai Nortye Ltd
Quotes are at least 15-min delayed:2024/05/14 19:03 EDT
Last
 13
0 (0.00%)
Day High 
13 
Prev. Close
13 
1-M High
15.55 
Volume 
6.63K 
Bid
11.6
Ask
13.6
Day Low
11.4903 
Open
12.65 
1-M Low
Market Cap 
479.70M 
Currency USD 
P/E -- 
%Yield
10-SMA 13.48 
20-SMA 12.87 
50-SMA 10.62 
52-W High 19.2999 
52-W Low 7.1114 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.26/--
Enterprise Value
480.17M
Balance Sheet
Book Value Per Share
2.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8628+0.0221+2.63%-- 
JAGXJaguar Health0.2749-0.0154-5.30%-- 
NVAXNovavax13.48+0.37+2.82%-- 
SCPXScorpius Holdings0.0768-0.1047-57.69%-- 
RXRXRecursion Pharmaceuticals10.05+0.57+6.01%-- 
Quotes are at least 15-min delayed:2024/05/14 19:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.